Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

Buparlisib (BKM120) is an oral pan-phosphatidylinositol 3-kinase inhibitor, targeting all four isoforms of class I PI3K (α, β, γ and δ). This open-label Phase I dose-escalation study was conducted to determine the maximum tolerated dose of continuous daily buparlisib in Japanese patients with advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Yuichi, Inada-Inoue, Megumi, Mitsuma, Ayako, Yoshino, Takayuki, Ohtsu, Atsushi, Suenaga, Naoko, Sato, Masahiko, Kakizume, Tomoyuki, Robson, Matthew, Quadt, Cornelia, Doi, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317947/
https://www.ncbi.nlm.nih.gov/pubmed/24405565
http://dx.doi.org/10.1111/cas.12350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317947/
https://www.ncbi.nlm.nih.gov/pubmed/24405565
http://dx.doi.org/10.1111/cas.12350

Ejemplares similares